These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31900503)

  • 1. Study of KIR gene expression at the mRNA level in specific donor-derived NK cells after allogeneic HSCT.
    Li Y; Wang T; Hu X; Zhang H; Chen L; Bao X; He J
    Immunogenetics; 2020 Apr; 72(3):135-141. PubMed ID: 31900503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic mRNA expression of donor-derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation.
    Li Y; Wang T; Hu X; Zhang H; Bao X; Wu D; He J
    Clin Exp Immunol; 2021 Sep; 205(3):417-428. PubMed ID: 34085290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune reconstruct regularity profile of KIR2DL1 and KIR3DL1 in unrelated-donor allogeneic hematopoietic stem cell transplantation].
    Hu X; He J; Zhang HH; Bao XJ; Wang M; Zhang J; Cen JN; Wu XJ; Yang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):667-672. PubMed ID: 28954344
    [No Abstract]   [Full Text] [Related]  

  • 4. [Distribution of donor-specific aKIR after unrelated allogeneic hematopoietic stem cell transplantation].
    Zhang HH; He J; Bao XJ; Hu X; Wang M; Zhang J; Wu XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 May; 38(5):421-426. PubMed ID: 28565743
    [No Abstract]   [Full Text] [Related]  

  • 5. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].
    Bao XJ; He J; Chen ZX; Wu DP; Yao L; Yuan XN; Cen JN; Qiu QC; Di WY; Zhang H; Zhang J; Zhou XH; Xu HX
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):510-3. PubMed ID: 18078124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
    Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
    Gaafar A; Sheereen A; Almohareb F; Eldali A; Chaudhri N; Mohamed SY; Hanbali A; Shaheen M; Alfraih F; El Fakih R; Iqneibi A; Youniss R; Elhassan T; Hashmi S; Aljurf M; Alhussein K
    Bone Marrow Transplant; 2018 Sep; 53(9):1170-1179. PubMed ID: 29549293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Distribution of immunoglobulin like receptor gene in Han population in China and the impact thereof on the HLA-identical sibling hematopoietic stem cell transplantation].
    Dou LP; DA WM; Zhao DD; Wang C; Lu XC; Kang HY; Yan P; Wang FF; Zhu HY; Li HH; Gao CJ; Yu L
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3111-4. PubMed ID: 18269867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
    Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
    Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT.
    Giebel S; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Nowak I; Holowiecka A; Segatti A; Kyrcz-Krzemien S; Kusnierczyk P; Holowiecki J
    Bone Marrow Transplant; 2010 Jun; 45(6):1022-30. PubMed ID: 20118994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
    Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
    Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of killer-cell immunoglobulin-like receptor genes with acute myelogenous leukaemia.
    Alavianmehr A; Mansouri M; Ramzi M; Faghih M; Monabati A; Arandi N; Faghih Z; Farjadian S
    Int J Immunogenet; 2020 Dec; 47(6):512-521. PubMed ID: 32767509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation.
    Zuo W; Yu XX; Liu XF; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Zhao XS; Huang XJ; Zhao XY
    Front Immunol; 2022; 13():814334. PubMed ID: 35572602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
    Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
    Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
    N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
    Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.